Stockreport

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

KalVista Pharmaceuticals, Inc.  (KALV) 
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.kalvista.com
PDF –Orphan drug designation paves the way for potential of sebetralstat to be first oral on-demand treatment for HAE in Japan–– Submission advances Company’s strategic plan [Read more]